Ahmad Safavy

Ahmad Safavy

Auto-generated profile, based on publicly available information

Ahmad Safavy

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAhmad Safavy
Ahmad Safavy
KRKevin P. Raisch
Kevin P. Raisch
SMSushma Mantena
Sushma Mantena
LSLeisa L. Sanford
Leisa L. Sanford
SSSimon W. Sham
Simon W. Sham
JBJames A. Bonner
James A. Bonner

1 November 1999 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAhmad Safavy
Ahmad Safavy
KRKevin P. Raisch
Kevin P. Raisch
MKM. B. Khazaeli
M. B. Khazaeli
DBDonald J. Buchsbaum
Donald J. Buchsbaum
JBJames A. Bonner
James A. Bonner

28 January 2003 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
ASAhmad Safavy
Ahmad Safavy
JBJames A. Bonner
James A. Bonner
HWHarlan W. Waksal
Harlan W. Waksal
DBDonald J. Buchsbaum
Donald J. Buchsbaum
GGG. Yancey Gillespie
G. Yancey Gillespie
KRKevin P. Raisch
Kevin P. Raisch

3 December 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SQSherly Quiles
Sherly Quiles
KRKevin P. Raisch
Kevin P. Raisch
LSLeisa L. Sanford
Leisa L. Sanford
JBJames A. Bonner
James A. Bonner
ASAhmad Safavy
Ahmad Safavy

1 January 2008 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
ASAhmad Safavy
Ahmad Safavy
Paclitaxel (taxol, 1a) and docetaxel (taxotere, 1b) have established themselves as an important class of antitumor drugs currently available to the oncologist. While the great contribution of these drugs to the management of the disease and their effect on the improvement of the patient quality of life could not be overemphasized, a great deal of research has been ongoing to improve two key pharmacologic factors, antitumor activity and systemic toxicity. Both physical and chemical means have been employed towards the enhancement of antitumor activity and at the same time, lowering the inherent toxicity and side effects of these drugs. This mini-review compiles the recent reported works on the design and development of taxane delivery systems through tumor cell surface receptortargeted delivery mechanisms such as small-molecule peptides and monoclonal antibodies, as well as those on non-targeted procedures such as liposomes, nanostructures, and natural and synthetic polymers.

16 February 2002 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
ASAhmad Safavy
Ahmad Safavy
DSDale C. Smith
Dale C. Smith
ABAlireza Bazooband
Alireza Bazooband
DBDonald J. Buchsbaum
Donald J. Buchsbaum